DJ-1 / PARK7 Program
Alzheimer's Disease, Parkinson's Disease
Pre-clinicalActive
Key Facts
Indication
Alzheimer's Disease, Parkinson's Disease
Phase
Pre-clinical
Status
Active
Company
About Cantabio Pharmaceuticals
Cantabio Pharmaceuticals is a preclinical-stage biotech targeting a fundamental biological mechanism—biochemical stress—to develop therapeutics for neurodegenerative and metabolic diseases. The company's strategy integrates a focus on intrinsically disordered proteins (IDPs) and novel drug discovery technologies, an approach recognized by the World Economic Forum. While still in the research and discovery phase, Cantabio has garnered attention through grants from The Michael J. Fox Foundation and publications validating targets like the DJ-1 protein in Alzheimer's and Parkinson's disease.
View full company profileTherapeutic Areas
Other Alzheimer's Disease, Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Neurodegeneration Program(s) | Muna Therapeutics | Preclinical |
| Neurodegenerative Diseases Biomarker Services | The Siesta Group | Service Offering |
| Undisclosed Neurodegeneration Program | Sitala Bio | Pre-clinical |